You will be shown the abstract of a medical clinical trial report. Your task is to extract all the findings from this report into a JSON array. Each finding should contain the following five elements:

- Intervention: The medical intervention being tested. This should be a text span copied from the input passage.
- Comparator: The baseline against which the intervention is being evaluated. This should be a text span copied from the input passage. If no comparator is reported, set to `null`.
- Outcome: The medical outcome whose effect is being measured. This should be a text span copied from the input passage.
- Effect: The effect of the intervention on the outcome, relative to the comparator. The effect should be one of the following three values: ("significantly increased", "significantly decreased", "no significant difference").
- Evidence: The evidence for the effect. This should be a text span copied from the input passage.

Please format your output as a JSON array. Each entry in the output should be an array containing the 5 elements listed above, in the following order: [<intervention>, <comparator>, <outcome>, <effect>, <evidence>].

For example, an output with two findings might read:
```
[["aspirin", "placebo", "headache severity", "significantly decreased", "Mean headache severity was significantly decreased in the aspirin group compared to the placebo group (p < 0.05)."], ["aspirin", "placebo", "weight loss", "no significant difference", "We did not observe any difference in weight loss between the group given aspirin relative to the control group"]]
```

There are 5 finding(s) in the abstract below. Please extract them. Output only the JSON array with these 5 findings. Do not include any additional text.

Abstract:
ABSTRACT.OBJECTIVE: To evaluate the efficacy, tolerability, and safety of once-daily 1200 mg and 2400 mg SPN-804 (Oxtellar XRTM, Supernus Pharmaceuticals), an extended-release tablet formulation of oxcarbazepine (OXC), added to 1-3 concomitant antiepileptic drugs (AEDs) in adults with refractory partial-onset seizures, with or without secondary generalization.

ABSTRACT.METHODS: The Prospective, Randomized Study of OXC XR in Subjects with Partial Epilepsy Refractory (PROSPER) study was a multinational, randomized, double-blind, parallel-group Phase 3 study. The primary efficacy endpoint was median percent reduction from baseline in monthly (28-day) seizure frequency for the 16-week double-blind treatment period in the intent-to-treat (ITT) population with analyzable seizure data. Other efficacy analyses included proportion of patients with ≥ 50% seizure reduction, proportion of patients seizure free, and the relationship between clinical response and plasma concentration.

ABSTRACT.RESULTS: Median percent reduction was -28.7% for placebo, −38.2% (P = 0.08 vs placebo) for once-daily SPN-804 1200 mg, and −42.9% (P = 0.003) for SPN-804 2400 mg. Responder rates were 28.1%, 36.1% (P = 0.08), and 40.7% (P = 0.02); 16-week seizure-free rates in a pragmatic ITT analysis were 3.3%, 4.9% (P = 0.59), and 11.4% (P = 0.008), respectively. When data were analyzed separately for study site clusters, a post hoc analysis demonstrated that both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: −13.3%; 1200 mg: −34.5%, P = 0.02; 2400 mg: −52.7%, P = 0.006) in the North American study site cluster. A concentration–response analysis also supported a clinically meaningful effect for 1200 mg. Adverse event types reflected the drug's established profile. Adverse event frequency was consistent with a pharmacokinetic profile in which SPN-804 produces lower peak plasma concentrations vs immediate-release OXC. Once-daily dosing was not associated with any new safety signals.

ABSTRACT.CONCLUSIONS: Adjunctive once-daily SPN-804 improved seizure control in patients with inadequately controlled partial-onset seizures. Adverse event occurrence and discontinuations due to adverse events suggest improved tolerability vs previously published data with immediate-release OXC.

Findings:
[["Extended-release oxcarbazepine 2400 mg", "Control", "Overall seizure median percent improvement ", "significantly increased", "Median percent reduction was -28.7% for placebo, \u221238.2% (P = 0.08 vs placebo) for once-daily SPN-804 1200 mg, and \u221242.9% (P = 0.003) for SPN-804 2400 mg"], ["Extended-release oxcarbazepine 2400 mg", "Control", "Overall seizure median percent improvement ", "significantly increased", "When data were analyzed separately for study site clusters, a post hoc analysis demonstrated that both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: \u221213.3%; 1200 mg: \u221234.5%, P = 0.02; 2400 mg: \u221252.7%, P = 0.006) in the North American study site cluster."], ["Extended-release oxcarbazepine 1200 mg", "Control", "Overall seizure median percent reduction", "no significant difference", "Median percent reduction was -28.7% for placebo, \u221238.2% (P = 0.08 vs placebo) for once-daily SPN-804 1200 mg, and \u221242.9% (P = 0.003) for SPN-804 2400 mg"], ["Extended-release oxcarbazepine 1200 mg", "Control", "Seizure median percent improvement in North America", "significantly increased", "both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: \u221213.3%; 1200 mg: \u221234.5%, P = 0.02; 2400 mg: \u221252.7%, P = 0.006)"], ["Extended-release oxcarbazepine 2400 mg", "Control", "Seizure median percent improvement in North America", "significantly increased", "both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: \u221213.3%; 1200 mg: \u221234.5%, P = 0.02; 2400 mg: \u221252.7%, P = 0.006) in the North American study site cluster"]]